The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease

TL;DR

This paper highlights the importance of vaccinations and specific antiviral treatment for patients with cardiovascular disease during the COVID-19 pandemic.

Contribution

The paper emphasizes the practical importance of tailored treatment and prevention strategies for cardiac patients with COVID-19.

Findings

Cardiovascular patients are at higher risk for severe COVID-19 outcomes.

Vaccinations are a safe and effective preventive measure for this group.

Nirmatrelvir/ritonavir is effective but requires careful drug interaction analysis.

Abstract

The COVID-19 pandemic posed a huge challenge to global health systems. In addition to searching for effective methods of treating and preventing infection with a new pathogen, we could once again observe that severe respiratory infection and its complications can be become a challenging problem for cardiac patients. Empirical observations are fully confirmed by the results of clinical trials. Patients with risk factors and already diagnosed with cardiovascular diseases are particularly exposed to the severe course of COVID-19, including death. That is why we consider it so important to promote vaccinations against COVID-19 as a safe and effective method of preventing serious infections in this special group of patients, in accordance with the updated recommendations of relevant experts. If an infection is detected, depending on its form and the risk of hospitalization, there are also several antiviral treatment strategies. Nirmatrelvir/ritonavir therapy is particularly effective in selected patient groups, but its use requires analysis of the cardiac pharmacotherapy regimen in the context of potentially significant drug interactions.

Figures